AML ASH 22
Naval Daver, MD, checks in at The HemOnc Pulse to discuss AML in the elderly and the emergence of venetoclax.
John DiPersio, MD, PhD, discusses menin inhibitors, current challenges in treating AML, the role of transplant, and more.
Jennifer R. Brown, MD, PhD; President of SOHO chats with Chadi Nabhan, MD, on the ALPINE study.
Advertisement
Matthew Davids, MD, MMSc, discusses ZUMA-8 results during the 2022 Annual American Society of Hematology Meeting.
Hispanics with AML had improved survival compared to non-Hispanic Blacks or non-Hispanic whites in a non-transplant setting.
Countries with a lower sociodemographic index are underrepresented in clinical trials of TKIs for the treatment of CML.
Advertisement
A whole-genome transcriptome sequencing study of hairy cell leukemia revealed a high degree of genomic complexity.
Maintenance therapy with venetoclax plus azacitidine may be a good option after transplant in high-risk acute leukemia.
The TKI ponatinib may be the optimal third-line therapy for patients with chronic myeloid leukemia.
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Triplet of Decitabine, Venetoclax, and Ponatinib Shows Promise in Myeloid Blast Phase CML or Ph+ AML
Decitabine, venetoclax, and ponatinib was well tolerated in patients with CML in myeloid blast phase or Ph-positive AML. 
Adherence to oral anticancer agents appeared to be good among adults with chronic myeloid leukemia (CML).
The use of venetoclax-containing therapy effectively bridged patients with relapsed or refractory AML.
Venetoclax plus HMAs led to higher response rates than non-venetoclax regimens in patients with newly diagnosed AML.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.